



10745 Westside Way, Suite 200, Alpharetta, GA USA 30009

Tel: +1 (844) 884 5367

Email: [info@vtivision.com](mailto:info@vtivision.com)

[www.vtvision.com](http://www.vtvision.com)

[www.vtvisioninvestors.com](http://www.vtvisioninvestors.com) (for investors)

## ASX Announcement

### Visioneering Technologies, Inc. Welcomes Senior Life Sciences Executive Jean Franchi to its Board of Directors

**Atlanta, Georgia, USA 19 December 2017:** Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses, is pleased to announce the appointment of Ms. Jean Franchi to its Board of Directors, and as Chair of the Audit and Risk Committee.

Ms. Franchi is a highly regarded business leader with over 20 years of experience in building and leading senior corporate and divisional financial teams from the research and development stage through product launch and commercial operations. Her experience spans both the public and private pharmaceutical, biotech, and diagnostics sectors. Ms. Franchi is currently the CFO of Merrimack Pharmaceuticals, Inc. (MACK), a NASDAQ listed biotechnology company specializing in oncology.

Visioneering's CEO, Dr. Stephen Snowdy said Ms. Franchi was a natural choice for the role, "Ms. Franchi brings to VTI immensely valuable skills, a wealth of experience, and great passion for taking both private and public companies from early market to full scale commercialization.

"Additionally, as VTI readies for international expansion, Ms. Franchi's experience in international operations is a highly valuable asset," Dr. Snowdy said.

Prior to Merrimack Pharmaceuticals, Ms. Franchi spent 16 years at Genzyme Corporation, a US-based biotechnology company now owned by Sanofi S.A., where she held roles of increasing responsibility and was instrumental in preparing the company for its transition from early market introductions to becoming the industry leader in rare disease drug development and commercialization.

Earlier in her career, Ms. Franchi worked in accounting, finance, and sales operations for two diagnostic companies: bioMérieux, Inc., and API, a former division of American Home Products (now Pfizer).

Ms. Franchi holds a Bachelor of Business Administration from Hofstra University, in New York.

ENDS.

**For more information, please contact:**

<b>Company</b>	<b>Investor and media relations</b>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a>	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: <a href="mailto:kwilliamson@we-buchan.com">kwilliamson@we-buchan.com</a>



10745 Westside Way, Suite 200, Alpharetta, GA USA 30009

Tel: +1 (844) 884 5367

Email: [info@vtivision.com](mailto:info@vtivision.com)

[www.vtvision.com](http://www.vtvision.com)

[www.vtvisioninvestors.com](http://www.vtvisioninvestors.com) (for investors)

**About VTI:**

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue® Multifocal (MF) contact lens. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

The NaturalVue MF contact lens employs VTI's Neurofocus Optics® technology, which was developed, refined and tested over many years. NaturalVue lenses were cleared by the FDA in late 2014 for the correction of refractive errors and VTI commenced a pilot US market launch of NaturalVue MF contact lenses from 2015 that gave way to a broader US launch in 2016 and 2017. VTI sells and plans additional contact lens products.

**Foreign ownership restrictions:**

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

MKT-VTI-PR47 r0